Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal

HOME

BIOKET DIGITAL EVENT | IBISBA Virtual B2B Meeting and Workshop on 2 July 2020

IBISBA within the global context of biofoundries and accelerated end-to-end bioprocess development

BIOKET DIGITAL EVENT | IBISBA Virtual B2B Meeting and Workshop on 2 July 2020
Join from any place, anywhere.

The IBISBA BIOKET event becomes digital, different formula, but with the same content and quality. On 2 July 2020 IBISBA welcomes you with a double appointment.


Digital Programme

Virtual B2B | 8.00 - 13.00 CEST

During this networking session you will be able to build new connections and to find new clients and potential partners relevant for your business.

Workshop | 14.00 - 17.30 CEST

During this session, experts will first set the scene and help us to appraise the current state of play in the biofoundry area and examine how biofoundries are likely to evolve in the future. Afterwards, the IBISBA concept will be spotlighted, looking at its biofoundry activities and how these fit into the wider framework of end-to-end bioprocess development which is being promoted by IBISBA. Moreover, we will examine some of the challenges related to injecting industry constraints into early phase bioprocess development. This session will bring together leading researchers from the IBISBA network of research facilities, a member of the Global Foundry Alliance and an industry player involved in the development of commercial biofoundries.

The workshop will be a lively combination of talks and debates in which the audience will be invited to play a full, active role providing feedback on their expectations regarding R&D infrastructure services, such as those proposed by IBISBA.


Guests Speakers

Prof. Paul FREEMONT | Imperatial College London, UK
Dr. Sunil Chandran | Amyris, USA

Chairperson: Dr Nic LINDKEY - CNRS France

  • Welcome & Introduction - Nic LINDLEY (Chair – CNRS, France)
  • Primer on biofoundries - Paul FREEMONT (Imperial College London, UK)
  • An industrial biofoundry - Sunil CHANDRAN (Amyris, USA)
  • IBISBA a Pan-European Infrastructure to support industrial biotechnology - Michael O'DONOHUE (Inrae, France)
  • Driving IBISBA's biofoundry operations using knowledge management and integration - Merja PENTTILA (VTT, Finland)
  • Scaling up or making industrial sense of biofoundry operations in IBISBA Katja Patzsch (IGB Fraunhofer, Germany)
  • ROUNDTABLE DISCUSSION with Olivier Rolland (TWB, France), Paul Freemont, Sunil Chandran, Katja Patzsch, Vitor Martins dos Santos (WUR, The Netherlands)

How to Register

Two passes are available for the Digital Event:

Digital Pass Workshop ONLY: FREE but registration is mandatory. Visit the BIOKET webpage and follow the instructions.

Digital Edition Pass (Workshop + online B2B): PAID.  Visit the Registration Page on the site for more information. The Digital Edition Pass  is automatically included with March 17-18 and full conference passes.

 

Context

The foundries that powered the industrial revolution took molten metal and cast it into items of different shapes that in turn became the parts of complex machines and industrial processes. Similarly, biofoundries aim to be places where DNA is combined to form bioparts that, once integrated into living microbial cells, will drive biological manufacturing processes. Unlike the foundries of old, biofoundries rely heavily on automation, using informatics and robotic systems to reproducibly design, build and validate complex molecular machineries. The recent appearance of biofoundries is linked to the growing importance of synthetic biology, a term that covers the use of advanced approaches for the design and construction of complex biological systems using the 'design- build-test' framework, borrowed from the information systems engineering area. Synthetic biology has greatly benefitted from systems biology, which provides ‘omic-scale’ data (DNA sequences, genome-wide metabolic maps, fluxomic data etc) that drives the design process, and from advanced DNA synthesis and microfluidics, which together provide the technology basis for this activity.

Using synthetic biology, researchers aim to accelerate the development of industrial biotechnology. However, it is widely recognised that while synthetic biology is making lab-scale production of molecules more tractable, it is still debatable about the extent to which synthetic biology is producing impact at the industrial scale. This is because, to achieve impact at the industrial scale it is necessary to go beyond design of the biocatalyst (the enzyme or the microbial cell), conceiving the whole bioprocess, including the way in which the target molecule will be extracted and purified.

IBISBA is an emerging, European-based distributed R&D infrastructure that integrates biofoundry operations into the wider framework of end-to-end bioprocess development, the aim being to deliver industry-ready processes.